Cantor Fitzgerald Predicts Verona Pharma FY2026 Earnings

Verona Pharma plc (NASDAQ:VRNA - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2026 earnings estimates for Verona Pharma in a research note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst O. Brayer expects that the company will post earnings of $12.56 per share for the year. Cantor Fitzgerald has a "Overweight" rating and a $100.00 price target on the stock. The consensus estimate for Verona Pharma's current full-year earnings is ($1.95) per share.

Several other equities analysts also recently issued reports on VRNA. TD Cowen began coverage on shares of Verona Pharma in a research note on Monday, April 28th. They set a "buy" rating and a $100.00 price target for the company. Jefferies Financial Group upped their price objective on shares of Verona Pharma from $95.00 to $110.00 and gave the company a "buy" rating in a report on Wednesday. Wells Fargo & Company lifted their price objective on shares of Verona Pharma from $93.00 to $107.00 and gave the company an "overweight" rating in a report on Wednesday, April 30th. Cowen initiated coverage on shares of Verona Pharma in a report on Monday, April 28th. They set a "buy" rating on the stock. Finally, Roth Capital set a $83.00 target price on Verona Pharma in a research note on Friday, February 28th. Nine investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $87.44.

Verona Pharma Price Performance

Verona Pharma stock traded up $2.45 during midday trading on Wednesday, reaching $92.50. The company's stock had a trading volume of 1,377,696 shares, compared to its average volume of 1,333,149. The stock has a market cap of $7.50 billion, a PE ratio of -48.18 and a beta of 0.21. The company has a current ratio of 13.03, a quick ratio of 12.88 and a debt-to-equity ratio of 0.93. The business has a 50-day moving average price of $70.32 and a 200-day moving average price of $59.90. Verona Pharma has a 52 week low of $14.14 and a 52 week high of $93.74.

Verona Pharma (NASDAQ:VRNA - Get Free Report) last released its quarterly earnings results on Tuesday, April 29th. The company reported $0.27 EPS for the quarter, beating the consensus estimate of ($0.22) by $0.49. The business had revenue of $98.65 million during the quarter, compared to analyst estimates of $41.47 million.

Insider Buying and Selling

In related news, CFO Mark W. Hahn sold 32,432 shares of Verona Pharma stock in a transaction on Tuesday, May 27th. The shares were sold at an average price of $9.53, for a total value of $309,076.96. Following the transaction, the chief financial officer now owns 13,046,560 shares in the company, valued at $124,333,716.80. This trade represents a 0.25% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Vikas Sinha sold 20,000 shares of Verona Pharma stock in a transaction dated Tuesday, April 29th. The stock was sold at an average price of $8.92, for a total value of $178,400.00. Following the completion of the transaction, the director now owns 74,440 shares in the company, valued at approximately $664,004.80. This represents a 21.18% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,085,800 shares of company stock worth $10,014,481. Corporate insiders own 4.80% of the company's stock.

Institutional Trading of Verona Pharma

Institutional investors have recently made changes to their positions in the stock. Acadian Asset Management LLC bought a new stake in shares of Verona Pharma in the 1st quarter worth approximately $48,000. Geneos Wealth Management Inc. increased its holdings in shares of Verona Pharma by 44.2% during the first quarter. Geneos Wealth Management Inc. now owns 630 shares of the company's stock valued at $40,000 after acquiring an additional 193 shares in the last quarter. Goldman Sachs Group Inc. increased its position in shares of Verona Pharma by 274.5% during the first quarter. Goldman Sachs Group Inc. now owns 1,041,408 shares of the company's stock valued at $66,119,000 after acquiring an additional 763,353 shares in the last quarter. Temasek Holdings Private Ltd bought a new position in Verona Pharma in the 1st quarter valued at approximately $2,012,000. Finally, Scientech Research LLC purchased a new stake in shares of Verona Pharma during the first quarter valued at $809,000. Hedge funds and other institutional investors own 85.88% of the company's stock.

Verona Pharma Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.